Utility of BRAF VE1 Immunohistochemistry as a Screening Tool for Colorectal Cancer Harboring BRAF V600E Mutation

BACKGROUND: BRAF mutation has been recognized as an important biomarker of colorectal cancer (CRC) for targeted therapy and prognosis prediction. However, sequencing for every CRC case is not cost-effective. An antibody specific for BRAF V600E mutant protein has been introduced, and we thus examined...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwon, Jeong-Hwa, Jeong, Byung-Kwan, Yoon, Yong Sik, Yu, Chang Sik, Kim, Jihun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Pathologists and the Korean Society for Cytopathology 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964290/
https://www.ncbi.nlm.nih.gov/pubmed/29590746
http://dx.doi.org/10.4132/jptm.2018.03.28

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964290/
https://www.ncbi.nlm.nih.gov/pubmed/29590746
http://dx.doi.org/10.4132/jptm.2018.03.28

Ejemplares similares